Table 4

Incidence and severity of hypersensitivity adverse events, all causality
Pegaptanib 0.3 mg
Number of Subjects With Diabetes Without Diabetes
(Nā€‰=ā€‰165) (Nā€‰=ā€‰1421)
Preferred Term1 n (%) Severe LT n (%) Severe LT
Blepharitis, allergic 0 0 0 0 1 (0.1) 0 0
Dermatitis, allergic 0 0 0 0 1 (0.1) 0 0
Dermatitis, contact 0 0 0 0 7 (0.5) 0 0
Drug hypersensitivity 0 0 0 0 6 (0.4) 0 0
Erythema 0 0 0 0 2 (0.1) 0 0
Hypersensitivity 0 0 0 0 2 (0.1) 0 0
Hypersensitivity NOS 0 0 0 0 5 (0.4) 0 0
Rash 0 0 0 0 2 (0.1) 0 0
Rash NOS 2 (1.2) 0 0 12 (0.8) 0 0
Toxic skin eruption 0 0 0 0 1 (0.1) 0 0
Urticaria 0 0 0 0 1 (0.1) 0 0

1Preferred terms are from MedDRA [Medical Dictionary for Regulatory Activities, version 12.1].

LT: life-threatening.

NOS: not otherwise specified.

Dombi et al.

Dombi et al. BMC Ophthalmology 2012 12:37   doi:10.1186/1471-2415-12-37

Open Data